Novel drugs in pediatric gliomas

Area of Science:

• Neuro-oncology
• Pediatric Oncology
• Pharmacology

Background:

• Gliomas are the most common primary brain tumors in adults and the second most frequent in children.
• Current treatments (surgery, chemotherapy, radiation) face challenges like treatment resistance, drug toxicity, and poor response rates in pediatric patients.
• There is a critical need for novel and more effective chemotherapeutic agents for pediatric gliomas.

Purpose of the Study:

• To review the latest updates in therapeutic drugs for pediatric gliomas.
• To highlight promising chemotherapeutic agents and novel approaches for glioma management.
• To provide insights into the evolving landscape of glioma treatment.

Main Methods:

• A comprehensive search of the PubMed electronic database was conducted.
• The review included pre-clinical and clinical controlled trials reporting on therapeutic drugs against gliomas.
• Literature was analyzed to identify emerging and effective treatment strategies.

Main Results:

• Therapeutic drug approaches for gliomas are evolving and show promise as a future treatment avenue.
• Several key chemotherapeutics are discussed, including alkylating agents (e.g., temozolomide), platinum derivatives, nitrosoureas, topoisomerase inhibitors, angiogenesis inhibitors, and cytomegalovirus-based therapies.
• The reviewed literature underscores the ongoing need for improved chemotherapeutic agents due to treatment limitations.

Conclusions:

• Novel therapeutic drugs represent a promising avenue for improving outcomes in pediatric glioma patients.
• Continued research into agents like alkylating agents, platinum derivatives, and targeted therapies is crucial.
• Developing more effective and less toxic chemotherapeutics is essential for addressing treatment resistance and improving response rates.